Document is current
Any future updates will be listed below
-
Authors
Mayer, Megan R.
Choo, Tse-Hwei
Javitt, Daniel C. https://orcid.org/0000-0003-2711-8239
Kantrowitz, Joshua T. https://orcid.org/0000-0003-1127-7016
-
Funding
Funding for this research was provided by:
internal funding (NYSPI) to JTK
- License Information
-
More Information
Article History
Received: 6 April 2026
Revised: 14 May 2026
Accepted: 9 June 2026
First Online: 17 June 2026
Competing interests
: There are no known conflicts that are directly relevant to this work. Dr Kantrowitz has received consulting payments within the last 24 months from Alphasights, techspert.io, Third Bridge, KeyQuest Health, MEDACorp, Clearview, Clarivate, ECRI Institute, Physicians Postgraduate Press, NAMCP, Medicys, Oliver Wyman, First Word, Tegus, Evercore, Medincell, ZaZa Research LLC, ExpertConnect, Antheum, Guidepoint. He has served on the Leal Advisory Boards in the past 24 months. He has conducted clinical research supported by the NIMH, Click, Alkermes, Alto and Boehringer Ingelheim within the last 24 months. He owns a small number of shares of common stock from GSK. Dr Javitt holds equity in NRx Pharmaceuticals and Glytech LLC/Inc. He holds patents for the use of NMDAR antagonists in the treatment of depression, pain, and PTSD; for MRI-guided TMS treatment of depression; and for EEG-based diagnosis of Alzheimer disease. The other authors reported no biomedical financial interests or potential conflicts of interest.
